WCM
CYTK icon

Weld Capital Management’s Cytokinetics CYTK Stock Holding History

Weld Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,774
Closed -$325K – 518
2020
Q2 		$325K Buy
+13,774
New +$258K 0.13% 255
2020
Q1 		– Sell
-18,294
Closed -$194K – 491
2019
Q4 		$194K Buy
+18,294
New +$188K 0.04% 537

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Weld Capital Management's CYTK Position: Q3 2020 in Review

Weld Capital Management sold out of Cytokinetics (CYTK) in Q3 2020, closing a stake of 13,774 shares — an estimated $325K sold.

Weld Capital Management first reported a position in CYTK in Q4 2019 and held it in 2 quarters. The position peaked at $325K in Q2 2020. 181 funds tracked by Wall St. Rank hold CYTK as of Q3 2020.

  • Weld Capital Management reported no remaining Cytokinetics position as of Q3 2020 after selling out during the quarter.
  • Weld Capital Management sold 13,774 Cytokinetics shares in Q3 2020, an estimated $325K.
  • Weld Capital Management first reported a position in Cytokinetics in Q4 2019 and held it in 2 quarters.
  • Weld Capital Management's Cytokinetics position peaked at $325K in Q2 2020.
  • 181 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2020.

Based on Weld Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.